Compare Viatris Inc (VTRS) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Financial Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $16.22 (market cap $18.69B), while Financial Select Sector SPDR Fund trades at $57.84. The key difference: Viatris Inc pays a 2.95% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| VTRS | XLF | |
|---|---|---|
Market Cap | $18.69B | — |
Sector | Health | — |
52-Week High | $17.86 | $58.01 |
52-Week Low | $9.49 | $47.80 |
Enterprise Value | $30.80B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
XLF, the Financial Select Sector SPDR ETF, trades at $57.73, down 0.14% on the day, with a bullish technical signal driven by moving averages. The ETF recently crossed above its 200-day moving average and hit a record high, supported by strong inflows into sector ETFs. A dividend of $0.19 is scheduled for June 2026.
Outlook remains positive given sector momentum and AI-driven opportunities, though overbought RSI levels and concentration risks warrant caution. Financials benefit from robust bank earnings and market broadening, but interest rate sensitivity and valuation pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
